|
|
|
|
| LEADER |
01984nmm a2200445 u 4500 |
| 001 |
EB002202345 |
| 003 |
EBX01000000000000001339548 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
240408 ||| eng |
| 100 |
1 |
|
|a Rapoport, Alan M.
|
| 245 |
0 |
0 |
|a Update on treatment of migraine
|h Elektronische Ressource
|c Alan M. Rapoport
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2024, 2024
|
| 300 |
|
|
|a 1 streaming video file (48 min.)
|b color, sound
|
| 505 |
0 |
|
|a Contents: Calcitonin Gene-Related Peptide (CGRP) -- Gepants -- Zavegepant nasal spray -- Monoclonal antibodies -- Ditans -- Remote upper arm neuromodulation (REN) -- Non-invasive vagal nerve stimulation -- Clinical trials -- Trigeminovascular system
|
| 653 |
|
|
|a Nasal Sprays
|
| 653 |
|
|
|a Calcitonin Gene-Related Peptide / metabolism
|
| 653 |
|
|
|a Antibodies, Monoclonal / therapeutic use
|
| 653 |
|
|
|a Headache / Treatment
|
| 653 |
|
|
|a Migraine Disorders / drug therapy
|
| 653 |
|
|
|a Migraine / Treatment
|
| 653 |
|
|
|a Drug Development
|
| 653 |
|
|
|a Clinical Trials as Topic
|
| 653 |
|
|
|a Calcitonin Gene-Related Peptide Receptor Antagonists
|
| 653 |
|
|
|a Analgesics / therapeutic use
|
| 653 |
|
|
|a Vagus Nerve Stimulation
|
| 653 |
|
|
|a Pain / drug therapy
|
| 653 |
|
|
|a Receptors, Serotonin / drug effects
|
| 653 |
|
|
|a Receptors, Calcitonin Gene-Related Peptide / drug effects
|
| 653 |
|
|
|a Receptor, Serotonin, 5-HT1F.
|
| 653 |
|
|
|a Migraine / Chemotherapy
|
| 653 |
|
|
|a Electric Stimulation Therapy
|
| 653 |
|
|
|a Migraine Disorders / therapy
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a Toward a deeper understanding of headache and migraine
|
| 500 |
|
|
|a Animated audio-visual presentation with synchronized narration. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/1115
|3 Series
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/5569
|x Verlag
|z Streaming video file
|
| 082 |
0 |
|
|a 570
|